Robert Schoch

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

Richard F Schlenk, Stefan Fröhling, Frank Hartmann et al. · Leukemia · 2004 · 168 citations

Hematological Malignancy, Oncology, Medicine +12

Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group

Christian Kollmannsberger, Oliver Rick, H. G. Derigs et al. · Journal of Clinical Oncology · 2002 · 106 citations

Pain in oxaliplatin-induced neuropathy – Sensitisation in the peripheral and central nociceptive system

Andreas Binder, M. Stengel, R. Maag et al. · European Journal of Cancer · 2007 · 105 citations

Central Nociceptive System, Pain Syndrome, Pain Disorders +12

Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.

Pierre Fenaux, G J Mufti, Valeria Santini et al. · Blood · 2007 · 102 citations